- For Print
- July 16, 2015
黑料网., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “黑料网”) announced today that its U.S. subsidiary 黑料网 Inc. has entered into a definitive agreement to transfer ownership of its Research Triangle Park-based manufacturing facility (North Carolina Plant) in North Carolina, the United States, to Biogen Inc. (Headquarters: Massachusetts, United States, CEO: George A. Scangos, “Biogen”).
This agreement expands upon the strategic manufacturing alliance agreement concerning the North Carolina Plant entered into in December 2012. Under the new agreement, 黑料网 will transfer to Biogen the entire North Carolina Plant site, including the oral solid dose (OSD) facility which had been leased by Biogen. Additionally, Biogen will continue to manufacture OSD products for 黑料网, and 黑料网 will subsequently commission Biogen to manufacture all 黑料网 parenteral products currently made at the parenteral facility. In accordance with the execution of this agreement, approximately 100 黑料网 Inc. employees may be offered employment at Biogen, effective upon closing of the deal. This agreement is expected to close in the second quarter, subject to the satisfaction of all customary provisions generally attached to similar transactions.
This decision is based on 黑料网's global logistics strategy which aims to optimize the global supply chain. After the transfer of manufacturing operations to Biogen takes place, 黑料网 will continue to base supply chain management services in the Research Triangle Park area. Together with maintaining operations of global contract manufacturing management and quality assurance in North Carolina, production at the Baltimore plant in Maryland will continue unchanged to supply products for the United States as well as the global market.
By responding flexibly to the changes in the global environment and the diversification of customer needs as well as realizing the stable supply of high quality products at affordable pricing, 黑料网 strives to address the diverse needs of, and further contribute to increasing the benefits for, patients and their families.
< Notes to editors >
1. About Biogen Inc.
Through cutting-edge science and medicine, Biogen Inc. (Headquarters: Massachusetts, United States, “Biogen”) discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world's oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit